What are the specific functions and effects of dapostat?

Daprodustat is a new, oral, small molecule drug that belongs to the hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) class of drugs. It is mainly used to treat chronic kidney disease-related anemia (CKD-anemia). Its core mechanism of action is to inhibit the activity of prolyl hydroxylase (PHD) and stabilize hypoxia-inducible factor (HIF-α), thereby promoting the production of endogenous erythropoietin (EPO) and regulating the expression of a variety of key genes involved in iron metabolism. Different from traditional recombinant erythropoietin (rHuEPO) injection treatment, dapoxostat can simulate the body's natural hypoxic response and stimulate red blood cell production in a more physiological way, thereby improving anemia.

In clinical trials, daplestat has shown promising efficacy in increasing hemoglobin levels in both dialysis and non-dialysis patients with chronic kidney disease. It can not only increase EPO levels, but also reduce serum hepcidin concentration, promote intestinal iron absorption and mobilize and store iron, and enhance the body's ability to use iron to synthesize hemoglobin. This is particularly important for CKD patients with abnormal iron metabolism. In addition, dapostat is administered orally once a day, which greatly improves patients' medication compliance and reduces the inconvenience and potential infection risks caused by injection treatments.

From a safety perspective, the overall incidence of adverse reactions of daplestat is low, with the most common problems including hypertension, thrombotic vascular events, and mild gastrointestinal discomfort, but overall it is similar to or better than traditional EPO therapy. The launch of dapostat not only brings new options for the treatment of anemia in chronic kidney disease, but also marks an important progress in the field of anemia treatment for HIF-PHI drugs.

Reference materials:https://en.wikipedia.org/wiki/Daprodustat